Discussion | The Table summarizes the ocular adverse events reported in published clinical trials of MEKIs. The 3 patients treated with MEKI A had no baseline abnormalities but developed CSC-like changes, with resolution after cessation of drug therapy. Similar self-limiting cases of CSC have been reported in other series. Urner-Bloch et al 2 reported that 13 of 20 patients treated with binimetinib for advanced cutaneous melanoma developed CSC, which resolved without cessation of treatment. van Dijk et al 3 propose that this retinopathy correlates with inhibition of the mitogen-activated protein kinase pathway in multiple retinal components.
To investigate the mechanism of MEKI-induced ocular toxic effects, Huang et al 4 administered the MEKI PD0325901
to rabbits by intravitreal injection, which reproduced retinal vascular occlusion and demonstrated potential mechanisms for retinal vein occlusion and CSC in MEKI-treated humans.
Retinal vein occlusion has been reported in association with the use of these agents, 1 but the hypercoagulable state of malignancy must be considered in this patient group. The case of central retinal vein occlusion we report here had no general systemic risk factors for retinal vein occlusion, and hypertension, diabetes, and hyperlipidemia were excluded. The taxanes paclitaxel and docetaxel are microtubulestabilizing agents used to treat a variety of malignant tumors and are associated with the development of cystoid macular edema. 5 The 3 patients described in this study were treated with a taxane in addition to an MEKI, presenting with retinal vein occlusion, ocular hypertension, and CSC, respectively. A possible mechanism for increased intraocular pressure in the context of MEK inhibition is that matrix metalloproteinase 2 secretion from human ciliary muscle is an extracellular signal-regulated kinase-dependent process. 6 Matrix metalloproteinases are integral to uveoscleral pathway function, and reduction of drainage of aqueous humor via this route can lead to increased intraocular pressure and subsequent glaucomatous optic neuropathy.
Conclusions | Because the role of MEKIs in this patient group is yet to be fully assessed, it is important that ocular complications are monitored prospectively using appropriate validated techniques. We recommend a baseline ophthalmic examination before starting MEKI treatment, including visual acuity and intraocular pressure measurements, dilated fundus examination, macular optical coherence tomography, and fundus photography. These cases highlight the wide spectrum of ocular adverse effects associated with the introduction of these drugs in clinical practice. This study confirms a previous observation 2,3 that some complications, particularly CSC, can resolve spontaneously. Further studies may help determine which patients may be at particular risk of ocular toxic effects. Abbreviations: CSC, central serous chorioretinopathy; MEKI, mitogen-activated protein kinase inhibitor.
Letters

The Rising Price of Cancer Drugs-A New Old Problem?
The high price of older drugs has been increasingly criticized in part because of recent dramatic price hikes. Last August, Turing Pharmaceuticals increased the price of pyrimethamine from $13.50 to $750 per tablet-a 5000% increasedrawing widespread ire. 1 More recently, the price of a 2-pack injectable epinephrine, EpiPen, was increased from $100 to more than $600. 2 Raising the price of older drugs seems particularly objectionable when one considers that the outlay for research and development occurred long ago, and has almost certainly already been recouped, 2 and it raises the question of how older drugs should be priced and valued. 
